Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
These companies are creating FDA-cleared apps that actually treat diseases—not just track symptoms. It's an entirely new category of medicine with massive growth potential.
A major catalyst is happening right now: insurers are increasingly covering these digital treatments, unlocking billions in potential revenue that wasn't accessible before.
Major pharmaceutical companies and healthcare systems are partnering with these innovators, signaling their belief in the technology's transformative potential.
Digital therapeutics represents the next evolution in healthcare, where FDA-cleared software serves as medicine itself. These companies create evidence-based interventions delivered directly to patients via apps and platforms, transforming treatment for chronic diseases, mental health conditions, and more.
This portfolio spans the digital health ecosystem, from specialized software developers to telehealth platforms and supportive technologies. A key catalyst is growing regulatory acceptance and new reimbursement pathways, validating both the clinical effectiveness and commercial potential of these innovations.
We've selected companies whose primary business involves creating software-based medical interventions, ensuring direct exposure to this innovative field. Many are seeing increasing insurance coverage decisions, which is critical for widespread adoption and long-term revenue growth.
This basket's total market capitalisation and its concentration among the largest constituents.
DRIO: $51.25M
TDOC: $1.53B
HIMS: $11.16B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+3
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
DARIOHEALTH CORP
DRIO
Current Price
$7.50
The company provides a global digital therapeutics (DTx) platform with personalized interventions for chronic conditions like diabetes and hypertensio...
The company provides a global digital therapeutics (DTx) platform with personalized interventions for chronic conditions like diabetes and hypertension.
TELADOC HEALTH INC
TDOC
Current Price
$6.59
As a major provider of virtual healthcare, its services include chronic condition management and mental health support delivered via its digital platf...
As a major provider of virtual healthcare, its services include chronic condition management and mental health support delivered via its digital platform.
HIMS & HERS HEALTH INC
HIMS
Current Price
$30.34
The company's consumer-first platform provides access to treatments for various chronic conditions via digital prescriptions and cloud pharmacy fulfil...
The company's consumer-first platform provides access to treatments for various chronic conditions via digital prescriptions and cloud pharmacy fulfillment.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+74.88%
On average, analysts expect assets in this group to grow 74.88% over the next year.
7 of 12 assets in this group are rated Buy by professional analysts.
